Clinical trial
Anlotinib Hydrochloride Therapy in Patients With Advanced Lung Cancer: A Real World Study.
NCT03940404 is registered in ClinicalTrials.gov with First People's Hospital of Hangzhou as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Anlotinib Hydrochloride Therapy in Patients With Advanced Lung Cancer: A Real World Study.
- Lead sponsor
- First People's Hospital of Hangzhou
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- May 31, 2019
- Completion date
- December 31, 2020
- Enrollment
- 1,000 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.